Brandon Huffman, MD

Clinical Investigator, Hale Family Center For Pancreatic Cancer Research

Department of Medical Oncology, Dana-Farber Cancer Institute

Instructor in Medicine, Harvard Medical School


Bio     Research Interests     Key Publications


Dr. Brandon Huffman, MD is a member of the DF/HCC Gastrointestinal Oncology disease center. He received his undergraduate and medical degrees from the University of Missouri in Columbia, Missouri. He trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota where he also served as a chief medical resident. He completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute/Mass General Brigham combined program where he also served as a chief fellow. He joined the faculty as a Medical Oncologist at the Dana-Farber Cancer Institute in 2023 and is currently an Instructor in Medicine at Harvard Medical School.

Research Interests

Dr. Huffman is a clinical investigator and translational researcher who is focused on bringing preclinical research ideas into clinic by designing and conducting innovative clinical trials using novel therapeutics for the treatment of pancreatic cancer. He and other Hale Center investigators have published one of the only clinical trials investigating the use of gemcitabine and nab-paclitaxel after progression or intolerance of first line treatment of pancreatic cancer with FOLFIRINOX. The trial helped establish a benchmark for future trials for pancreatic cancer. He used those data as the principal investigator to design a second line pancreatic cancer trial studying the use of gemcitabine and a WEE1 inhibitor collaborating on correlative analyses with other Hale Center laboratory investigators.

Key Publications

Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse M, Beg MS, Murphy JE, Mavroukakis S, Zaki A, Schlechter BL, Sanoff H, Manz C, Wolpin BM, Arlen P, Lacy J, Cleary JM. Effect of a MUC5AC antibody (NPC-1C) administered in combination with gemcitabine and nab-paclitaxel on survival in advanced pancreatic adenocarcinoma previously treated with FOLFIRINOX: a randomized clinical trial. JAMA Network Open. 2023 Jan 3; 6(1):e2249720. PMID: 36602796

Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hanningan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D’Andrea AD, Aguirre AJ, Shapiro GI, Cleary JM. A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2023. PMID: 37819936

Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JM. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers 2022, Dec 16;14(24):6223. PMID: 36551707; PMCID: PMC9776746

Cleary JM, Wolpin BM, Dougan SK, Raghavan S, Singh H, Huffman B, Sethi NS, Nowak JA, Shapiro GI, Aguirre AJ, D’Andrea AD. Opportunities for utilization of DNA repair inhibitors in homologous recombination repair-deficient and proficient pancreatic adenocarcinoma. Clin Cancer Res. 2021 Dec 15;27(24):6622-37. PMID: 34285063; PMCID: PMC8678153.

Comments are closed.